Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality.

[1]  S. Wilson,et al.  Durable Clinical Effectiveness with Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial , 2020 .

[2]  D. Scheinert,et al.  Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. , 2019, JACC. Cardiovascular interventions.

[3]  S. Parikh,et al.  Mortality Assessment of Paclitaxel-Coated Balloons , 2019, Circulation.

[4]  A. Tzafriri,et al.  Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Torguson,et al.  Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall. , 2019, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  D. Scheinert,et al.  Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions , 2019, Circulation. Cardiovascular interventions.

[7]  S. Spiliopoulos,et al.  Response to Letter by Bonassi on Article, “Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials” , 2019, Journal of the American Heart Association.

[8]  J. Beckman,et al.  Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. , 2019, Journal of the American College of Cardiology.

[9]  J. Beckman,et al.  Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices , 2019, JAMA cardiology.

[10]  Lohit Garg,et al.  TREATING POSTPARTUM REFRACTORY LONG QT SYNDROME WITH CERVICAL GANGLION SYMPATHECTOMY , 2019, Journal of the American College of Cardiology.

[11]  M. Shishehbor,et al.  Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon. , 2019, Journal of the American College of Cardiology.

[12]  R. Virmani,et al.  Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. , 2019, Journal of vascular and interventional radiology : JVIR.

[13]  S. Spiliopoulos,et al.  Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials , 2018, Journal of the American Heart Association.

[14]  J. Granada,et al.  Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results. , 2018, JACC. Cardiovascular interventions.

[15]  M. Bacharach,et al.  A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial , 2018, The Lancet.

[16]  R. Virmani,et al.  Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries. , 2018, Journal of vascular and interventional radiology : JVIR.

[17]  H. Garcia-Garcia,et al.  Letter by Dan et al Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial". , 2018, Circulation. Cardiovascular interventions.

[18]  D. Scheinert,et al.  12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment. , 2018, JACC. Cardiovascular interventions.

[19]  Hong Wang,et al.  Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries , 2018, Circulation. Cardiovascular interventions.

[20]  P. Faries,et al.  Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease , 2017, Circulation.

[21]  C. Paetzel,et al.  The 24-Month Results of the Lutonix Global SFA Registry: Worldwide Experience With Lutonix Drug-Coated Balloon. , 2017, JACC. Cardiovascular interventions.

[22]  R. Virmani,et al.  Comparison of Particulate Embolization after Femoral Artery Treatment with IN.PACT Admiral versus Lutonix 035 Paclitaxel-Coated Balloons in Healthy Swine. , 2016, Journal of vascular and interventional radiology : JVIR.

[23]  T. Ibrahim,et al.  Downstream Panniculitis Secondary to Drug-Eluting Balloon Angioplasty. , 2016, JACC. Cardiovascular interventions.

[24]  M. Dake,et al.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.

[25]  K. Katsanos,et al.  Paclitaxel-coated balloons and aneurysm formation in peripheral vessels. , 2015, Journal of vascular surgery.

[26]  D. Scheinert,et al.  Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapoplit , 2015, JACC. Cardiovascular interventions.

[27]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[28]  M. Shibuya,et al.  Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. , 2015, JACC. Cardiovascular interventions.

[29]  Y. Kihara,et al.  Slow-flow phenomenon after Paclitaxel-coated balloon angioplasty: findings from optical coherence tomography and coronary angioscopy. , 2015, JACC. Cardiovascular interventions.

[30]  D. Scheinert,et al.  Paclitaxel-Releasing Balloon in Femoropopliteal Lesions Using a BTHC Excipient , 2015, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[31]  R. Varcoe,et al.  Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon. , 2014, Journal of vascular surgery.

[32]  R. Virmani,et al.  Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans , 2014, Circulation.

[33]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[34]  PTCA with drug‐coated balloons is associated with immediate decrease of coronary flow reserve , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[35]  L. Dean,et al.  Aneurysm formation after drug‐eluting balloon treatment of drug‐eluting in‐stent restenosis: First case report , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[36]  R. Langer,et al.  Ethnic-specific prevalence of peripheral arterial disease in the United States. , 2007, American journal of preventive medicine.

[37]  S. Silber,et al.  High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. , 2004, Journal of the American College of Cardiology.

[38]  M. Böhm,et al.  Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis , 2004, Circulation.

[39]  I. Barasoain,et al.  Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. , 2003, Current cancer drug targets.

[40]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.